Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Identifieur interne : 000B47 ( Main/Exploration ); précédent : 000B46; suivant : 000B48Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Auteurs : RBID : pubmed:22743249English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Animals, Antibodies, Bispecific (adverse effects), Antibodies, Bispecific (therapeutic use), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Carcinoembryonic Antigen (immunology), Disease Progression, Humans, Male, Mice, Middle Aged, Neoplasm Metastasis, Pentetic Acid (immunology), Radioimmunotherapy (adverse effects), Radioimmunotherapy (methods), Survival Analysis, Thyroid Neoplasms (metabolism), Thyroid Neoplasms (pathology), Thyroid Neoplasms (radiotherapy), Treatment Outcome, Tumor Markers, Biological (metabolism), Young Adult.
- MESH :
- chemical , adverse effects : Antibodies, Bispecific, Antibodies, Monoclonal, Humanized.
- chemical , immunology : Carcinoembryonic Antigen, Pentetic Acid.
- chemical , metabolism : Tumor Markers, Biological.
- chemical , therapeutic use : Antibodies, Bispecific, Antibodies, Monoclonal, Humanized.
- adverse effects : Radioimmunotherapy.
- metabolism : Thyroid Neoplasms.
- methods : Radioimmunotherapy.
- pathology : Thyroid Neoplasms.
- radiotherapy : Thyroid Neoplasms.
- Adult, Aged, Aged, 80 and over, Animals, Disease Progression, Humans, Male, Mice, Middle Aged, Neoplasm Metastasis, Survival Analysis, Treatment Outcome, Young Adult.
Abstract
The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term survival based on such prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling times (DTs). This prospective phase II multicenter trial evaluated the efficacy and safety of anti-CEA pretargeted radioimmunotherapy (pRAIT) in rapidly progressing metastatic MTC patients and also how serum biomarker DTs correlate with clinical outcome.
DOI: 10.2967/jnumed.111.101865
PubMed: 22743249
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.</title><author><name sortKey="Salaun, Pierre Yves" uniqKey="Salaun P">Pierre-Yves Salaun</name><affiliation wicri:level="1"><nlm:affiliation>Nuclear Medicine Department, University Hospital and ICO Gauducheau Cancer Institute, IRCNA, Cancer Research Center, Université de Nantes, Inserm, UMR 892, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nuclear Medicine Department, University Hospital and ICO Gauducheau Cancer Institute, IRCNA, Cancer Research Center, Université de Nantes, Inserm, UMR 892, Nantes</wicri:regionArea><placeName><region type="région">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Campion, Loic" uniqKey="Campion L">Loïc Campion</name></author><author><name sortKey="Bournaud, Claire" uniqKey="Bournaud C">Claire Bournaud</name></author><author><name sortKey="Faivre Chauvet, Alain" uniqKey="Faivre Chauvet A">Alain Faivre-Chauvet</name></author><author><name sortKey="Vuillez, Jean Philippe" uniqKey="Vuillez J">Jean-Philippe Vuillez</name></author><author><name sortKey="Taieb, David" uniqKey="Taieb D">David Taieb</name></author><author><name sortKey="Ansquer, Catherine" uniqKey="Ansquer C">Catherine Ansquer</name></author><author><name sortKey="Rousseau, Caroline" uniqKey="Rousseau C">Caroline Rousseau</name></author><author><name sortKey="Borson Chazot, Francoise" uniqKey="Borson Chazot F">Françoise Borson-Chazot</name></author><author><name sortKey="Bardet, Stephane" uniqKey="Bardet S">Stéphane Bardet</name></author><author><name sortKey="Oudoux, Aurore" uniqKey="Oudoux A">Aurore Oudoux</name></author><author><name sortKey="Cariou, Bertrand" uniqKey="Cariou B">Bertrand Cariou</name></author><author><name sortKey="Mirallie, Eric" uniqKey="Mirallie E">Eric Mirallié</name></author><author><name sortKey="Chang, Chien Hsing" uniqKey="Chang C">Chien-Hsing Chang</name></author><author><name sortKey="Sharkey, Robert M" uniqKey="Sharkey R">Robert M Sharkey</name></author><author><name sortKey="Goldenberg, David M" uniqKey="Goldenberg D">David M Goldenberg</name></author><author><name sortKey="Chatal, Jean Francois" uniqKey="Chatal J">Jean-François Chatal</name></author><author><name sortKey="Barbet, Jacques" uniqKey="Barbet J">Jacques Barbet</name></author><author><name sortKey="Kraeber Bodere, Francoise" uniqKey="Kraeber Bodere F">Françoise Kraeber-Bodéré</name></author></titleStmt><publicationStmt><date when="2012">2012</date><idno type="doi">10.2967/jnumed.111.101865</idno><idno type="RBID">pubmed:22743249</idno><idno type="pmid">22743249</idno><idno type="wicri:Area/Main/Corpus">000C22</idno><idno type="wicri:Area/Main/Curation">000C22</idno><idno type="wicri:Area/Main/Exploration">000B47</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Antibodies, Bispecific (adverse effects)</term><term>Antibodies, Bispecific (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Carcinoembryonic Antigen (immunology)</term><term>Disease Progression</term><term>Humans</term><term>Male</term><term>Mice</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Pentetic Acid (immunology)</term><term>Radioimmunotherapy (adverse effects)</term><term>Radioimmunotherapy (methods)</term><term>Survival Analysis</term><term>Thyroid Neoplasms (metabolism)</term><term>Thyroid Neoplasms (pathology)</term><term>Thyroid Neoplasms (radiotherapy)</term><term>Treatment Outcome</term><term>Tumor Markers, Biological (metabolism)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Bispecific</term><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Carcinoembryonic Antigen</term><term>Pentetic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tumor Markers, Biological</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Bispecific</term><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Radioimmunotherapy</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radioimmunotherapy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Animals</term><term>Disease Progression</term><term>Humans</term><term>Male</term><term>Mice</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Survival Analysis</term><term>Treatment Outcome</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term survival based on such prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling times (DTs). This prospective phase II multicenter trial evaluated the efficacy and safety of anti-CEA pretargeted radioimmunotherapy (pRAIT) in rapidly progressing metastatic MTC patients and also how serum biomarker DTs correlate with clinical outcome.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22743249</PMID><DateCreated><Year>2012</Year><Month>08</Month><Day>02</Day></DateCreated><DateCompleted><Year>2012</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation></Journal><ArticleTitle>Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.</ArticleTitle><Pagination><MedlinePgn>1185-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.111.101865</ELocationID><Abstract><AbstractText Label="UNLABELLED">The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term survival based on such prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling times (DTs). This prospective phase II multicenter trial evaluated the efficacy and safety of anti-CEA pretargeted radioimmunotherapy (pRAIT) in rapidly progressing metastatic MTC patients and also how serum biomarker DTs correlate with clinical outcome.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From June 2004 to January 2008, 42 patients were treated with anti-CEA × anti-diethylenetriaminepentaacetic acid (DTPA) bispecific antibody (hMN-14 × m734) (40 mg/m(2)), followed by (131)I-di-DTPA-indium bivalent hapten (1.8 GBq/m(2)) 4-6 d later.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The disease control rate (durable stabilization plus objective response) was 76.2%. Grade 3-4 hematologic toxicity was observed in 54.7% of patients and myelodysplastic syndrome in 2, including 1 heavily treated previously. After pRAIT, 21 of 37 assessed patients (56.7%) showed a significant impact on DT (≥100% increase of pre-pRAIT calcitonin or CEA DT or prolonged decrease of the biomarker concentration after pRAIT). Pre-pRAIT DT and post-pRAIT DT were significant independent predictors for overall survival (OS) from pRAIT (pre-pRAIT: hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.24-0.86; P = 0.016; and post-pRAIT: HR, 5.32; 95% CI, 1.63-17.36; P = 0.006) and OS from diagnosis (pre-pRAIT: HR, 0.21; 95% CI, 0.08-0.51; P = 0.001; and post-pRAIT: HR, 6.16; 95% CI, 1.81-20.98; P = 0.004).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">pRAIT showed antitumor activity, with manageable hematologic toxicity in progressive MTC. Increased biomarker DT after treatment correlated with increased OS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salaun</LastName><ForeName>Pierre-Yves</ForeName><Initials>PY</Initials><Affiliation>Nuclear Medicine Department, University Hospital and ICO Gauducheau Cancer Institute, IRCNA, Cancer Research Center, Université de Nantes, Inserm, UMR 892, Nantes, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Loïc</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bournaud</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Faivre-Chauvet</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vuillez</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Taieb</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ansquer</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Borson-Chazot</LastName><ForeName>Françoise</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bardet</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Oudoux</LastName><ForeName>Aurore</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cariou</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Mirallié</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chien-Hsing</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Sharkey</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Goldenberg</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Chatal</LastName><ForeName>Jean-François</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kraeber-Bodéré</LastName><ForeName>Françoise</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial, Phase II</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Tumor Markers, Biological</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease">Thyroid cancer, medullary</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName MajorTopicYN="N">adverse effects</QualifierName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName MajorTopicYN="N">adverse effects</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunotherapy</DescriptorName><QualifierName MajorTopicYN="N">adverse effects</QualifierName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">pathology</QualifierName><QualifierName MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tumor Markers, Biological</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">jnumed.111.101865</ArticleId><ArticleId IdType="doi">10.2967/jnumed.111.101865</ArticleId><ArticleId IdType="pubmed">22743249</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22743249
|texte= Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22743249" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |